MX2023011469A - Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3. - Google Patents

Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3.

Info

Publication number
MX2023011469A
MX2023011469A MX2023011469A MX2023011469A MX2023011469A MX 2023011469 A MX2023011469 A MX 2023011469A MX 2023011469 A MX2023011469 A MX 2023011469A MX 2023011469 A MX2023011469 A MX 2023011469A MX 2023011469 A MX2023011469 A MX 2023011469A
Authority
MX
Mexico
Prior art keywords
muc16
bispecific antibodies
formulations containing
human
stabilized formulations
Prior art date
Application number
MX2023011469A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Kamen
Xiaobin Xu
Haibo Qiu
Kenneth Graham
Teng-Chieh Yang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023011469A publication Critical patent/MX2023011469A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
MX2023011469A 2021-04-02 2022-04-01 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3. MX2023011469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170320P 2021-04-02 2021-04-02
US202263313927P 2022-02-25 2022-02-25
PCT/US2022/023122 WO2022212885A1 (en) 2021-04-02 2022-04-01 Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2023011469A true MX2023011469A (es) 2024-02-01

Family

ID=81579790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011469A MX2023011469A (es) 2021-04-02 2022-04-01 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3.

Country Status (13)

Country Link
US (1) US20220332849A1 (enExample)
EP (1) EP4313008A1 (enExample)
JP (1) JP2024513835A (enExample)
KR (1) KR20230165828A (enExample)
AU (1) AU2022246687A1 (enExample)
BR (1) BR112023019096A2 (enExample)
CA (1) CA3213546A1 (enExample)
CL (1) CL2023002922A1 (enExample)
CO (1) CO2023014918A2 (enExample)
IL (1) IL306042A (enExample)
MX (1) MX2023011469A (enExample)
TW (1) TW202304507A (enExample)
WO (1) WO2022212885A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체

Also Published As

Publication number Publication date
WO2022212885A1 (en) 2022-10-06
CA3213546A1 (en) 2022-10-06
EP4313008A1 (en) 2024-02-07
CL2023002922A1 (es) 2024-03-08
JP2024513835A (ja) 2024-03-27
AU2022246687A1 (en) 2023-10-12
AU2022246687A9 (en) 2023-10-26
KR20230165828A (ko) 2023-12-05
US20220332849A1 (en) 2022-10-20
BR112023019096A2 (pt) 2023-12-05
CO2023014918A2 (es) 2023-11-20
TW202304507A (zh) 2023-02-01
IL306042A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
PH12019502123A1 (en) Stable antibody formulation
JO3417B1 (ar) الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
MY164610A (en) Stabilized formulations containing anti-ngf antibodies
MX2019008084A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
NZ592918A (en) Antibody formulation comprising an IL-1beta antibody and a buffer
PH12021552092A1 (en) Stabilized formulations containing anti-il-33 antibodies
MX2022015734A (es) Proteinas de exotoxina a modificadas.
MX2024012567A (es) Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso
MX2021005085A (es) Formulacion de anticuerpo.
WO2019085982A8 (zh) 一种抗pd-l1人源化单克隆抗体的药物组合物
PH12022551275A1 (en) Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies
CO2023014918A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
CO2026000834A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3
MX2022016218A (es) Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4.
AR125292A1 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficosanti-muc16 x anti-cd3
CY1125584T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
MX2024016091A (es) Formulaciones de anticuerpos anti-pd-1
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
MX2025010272A (es) Formulaciones de anticuerpos anti-fel d1